the paucity of MKs. The cloning and characterization of the primary regulator of thrombopoiesis, thrombopoietin (TPO), in 1994 greatly facilitated our understanding of platelet production.
Thrombopoiesis is a complex process that induces the commitment of multipotent stem cells to the MK lineage, MK progenitor proliferation, and terminal differentiation, inducing platelet production [1] . TPO controls thrombopoiesis by affecting the proliferation and/or apoptosis of progenitor cells, as well as MKs ploidy. Moreover, TPO supports the proliferation of hematopoietic stem cells (HSCs) and progenitor cells. In vitro colony assays using bone marrow from TPO -/-and/or c-Mpl -/-mice show a reduction of CFU-mix, CFU-GM and BFU-E progenitors. Although RBC and white blood cell (WBC) counts in peripheral blood are normal in TPO -/-and c-Mpl -/-mice, despite the marked thrombocytopenia, and do not reflect the multilineage effect of TPO, TPO can shorten the duration of anemia and leukopenia in an experimental mouse model under myelosuppressive conditions [2] . In addition to TPO, MK-active chemokines, stromal-derived factor (SDF)-1, and a fibroblast growth factor (FGF-4), direct MK interaction with the bone marrow stroma and regulate TPO-independent cell maturation, and restore thrombopoiesis in TPO -/-and c-Mpl -/-mice [3] . A recent report of in vivo imaging of thrombopoiesis in mouse bone marrow revealed that MKs are enriched at bone marrow sinusoids and observed as sessile cells that extend dynamic proplatelet-like protrusions into microvessels, and that these cells routinely release heterogeneous particles, with properties resembling immature proplatelets, into BM microvessels [4] .
In this issue of IJH, in light of the approval of TPO receptor agonists in the treatment of primary immune thrombocytopenia and significant advances in the field of Y. Tomiyama (&) Osaka University Hospital, Suita, Osaka, Japan e-mail: yoshi@hp-blood.med.osaka-u.ac.jp megakaryopoiesis and thrombopoiesis, we focus on the pathophysiology of various thrombocytopenic disorders, including primary immune thrombocytopenia, inherited thrombocytopenias, aplastic anemia, and myelodysplastic syndromes, and the possible clinical application of TPO receptor agonists to these pathological conditions, following a comprehensive and informative overview of the biology of TPO and TPO receptor agonists. As a member of the editorial board, it is my hope that our readers will enjoy the excellent review articles in this PIH series and gain a better understanding of the pathophysiology these thrombocytopenic disorders.
